HRP20191171T1 - Kombinacije lijekova - Google Patents

Kombinacije lijekova Download PDF

Info

Publication number
HRP20191171T1
HRP20191171T1 HRP20191171TT HRP20191171T HRP20191171T1 HR P20191171 T1 HRP20191171 T1 HR P20191171T1 HR P20191171T T HRP20191171T T HR P20191171TT HR P20191171 T HRP20191171 T HR P20191171T HR P20191171 T1 HRP20191171 T1 HR P20191171T1
Authority
HR
Croatia
Prior art keywords
combination
formula
kit
compound
cancer
Prior art date
Application number
HRP20191171TT
Other languages
English (en)
Inventor
Mohammad Azab
Pietro Taverna
Alessia COVRE
Sandra CORAL
Original Assignee
Astex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Pharmaceuticals, Inc. filed Critical Astex Pharmaceuticals, Inc.
Publication of HRP20191171T1 publication Critical patent/HRP20191171T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (30)

1. Kombinacija koja sadrži sljedeće odvojene komponente: (i) spoj s Formulom I ili njegovu farmaceutski prihvatljivu sol: (5-azacitozinska skupina)-L-(gvaninska skupina) (I) pri čemu L je poveznica koja sadrži fosfor Formule (II): pri čemu, R1 i R2 su neovisno H, OH, alkoksi skupina, alkoksialkoksi skupina, aciloksi skupina, karbonatna skupina, karbamatna skupina, ili halogen; R3 je H, ili R3 zajedno s kisikovim atomom na koji je R3 vezan tvore eter, ester, karbonat, ili karbamat; R4 je H, ili R4 zajedno s kisikovim atomom na koji je R4 vezan tvore eter, ester, karbonat, ili karbamat; i X zajedno s kisikovim atomima na koje je X vezan tvore fosfodiester, fosforotioatni diester, boranofosfatni diester, ili metilfosfonatni diester; i (ii) jednu ili više pomoćnih terapijskih komponenti, pri čemu je navedena pomoćna terapijska komponenta sredstvo za aktiviranje T-stanica; pri čemu navedeni spoj s Formulom I, ili njegova farmaceutski prihvatljiva sol, je za primjenu prije navedene pomoćne terapijske komponente.
2. Kombinacija prema patentnom zahtjevu 1, naznačena time što R1 i R2 su neovisno H, OH, OMe, OEt, OCH2CH2OMe, OBn, ili F, a poželjno R1 i R2 su H.
3. Kombinacija prema patentnom zahtjevu 1 ili zahtjevu 2 naznačena time što X zajedno s atomima kisika na koje je X vezan tvori fosfodiester.
4. Kombinacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što spoj s Formulom I je bilo koji od I-(1-44):
i njihove farmaceutski prihvatljive soli.
5. Kombinacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što spoj s Formulom I je:
6. Kombinacija prema bilo kojem od prethodnih patentnih zahtjeva naznačena time što spoj s Formulom I ima formulu: ili njegova farmaceutski prihvatljiva sol.
7. Kombinacija prema patentnom zahtjevu 6 naznačena time što je navedena sol natrijeva sol.
8. Kombinacija prema bilo kojem od prethodnih patentnih zahtjeva naznačena time što je spoj s Formulom I ili njegova sol u obliku formulacije, otopljena u uglavnom bezvodnom otapalu koje sadrži 45% do 85% propilen glikola; 5% do 45% glicerina; i 0% do 30% etanola.
9. Kombinacija prema bilo kojem prethodnom patentnom zahtjevu naznačena time što je spoj s Formulom I ili njegova sol prisutna u formulaciji u koncentraciji od 80 mg/mL do 110 mg/mL.
10. Kombinacija prema patentnom zahtjevu 8 naznačena time što je formulacija pogodna za primjenu potkožnom injekcijom.
11. Komplet koji sadrži: (a) prvu posudu koja sadrži spoj s Formulom I ili njegovu sol kako je definirano u bilo kojem od zahtjeva 1-7; (b) drugu posudu koja sadrži uglavnom bezvodno otapalo kako je definirano u zahtjevu 8; i (c) jednu ili više pomoćnih terapijskih komponenti kako je definirano u zahtjevu 1; pri čemu je navedeni spoj s Formulom I za primjenu prije navedene ne ili više pomoćnih terapijskih komponenti.
12. Komplet prema patentnom zahtjevu 11 naznačen time što je spoj s Formulom I u obliku uglavnom bezvodnog praha, te je poželjnije liofiliziran.
13. Komplet prema bilo kojem od patentnih zahtjeva 11-12 naznačen time što prva posuda sadrži 80 mg do 110 mg navedenog spoja Formule I ili njegove soli.
14. Komplet prema bilo kojem od patentnih zahtjeva 11-13 naznačen time što nadalje sadrži upute za davanje potkožnom injekcijom.
15. Kombinacija prema bilo kojem od patentnih zahtjeva 1-10 ili komplet prema bilo kojem od patentnih zahtjeva 11-14, naznačena time što pomoćna terapijska komponenta sadrži: (a) sredstvo za aktiviranje T-stanica i cjepivo za karcinom; ili (b) sredstvo za aktiviranje T-stanica i inhibitor IDO; proizvoljno pri čemu pomoćna terapijska komponenta nadalje sadrži adjuvans.
16. Kombinacija prema bilo kojem od patentnih zahtjeva 1-10 ili komplet prema bilo kojem od patentnih zahtjeva 11-14 naznačena time što pomoćna terapijska komponenta sadrži sredstvo za aktiviranje T-stanica koje je odabrano od agonista ili protutijela za: ICOS, GITR, MHC, CD80, CD86, Galektin 9 i LAG-3.
17. Kombinacija prema bilo kojem od patentnih zahtjeva 1-10 ili komplet prema bilo kojem od patentnih zahtjeva 11-14 naznačena time što sredstvo za aktiviranje T-stanica je protutijelo odabrano iz niza koji sadrži: (a) CD137 agonist; (b) CD40 agonist; (c) OX40 agonist; (d) PD-1 mAb; (e) PD-L1 mAb; (f) PD-L2 mAb; (g) CTLA-4 mAb; i (h) kombinacije od (a)-(g).
18. Kombinacija prema bilo kojem od patentnih zahtjeva 1-10 ili komplet prema bilo kojem od patentnih zahtjeva 11-14 naznačena time što sredstvo za aktiviranje T-stanica je protutijelo, i protutijelo sadrži protutijelo odabrano iz niza koji sadrži: (a) Tremelimumab; (b) Ipilimumab; (c) Nivolumab; (d) Lambrolizumab; (e) BMS-936559; (f) MEDI4736; (g) MPDL3280A; i (h) PF-05082566.
19. Kombinacija ili komplet prema bilo kojem prethodnom zahtjevu naznačena time što se koristi za liječenje bolesti odabrane od: (a) mijelodisplastičnog sindroma (MDS); (b) raka; (c) hematološkog poremećaja; i (d) bolesti povezane s abnormalnom sintezom hemoglobina; pri čemu se spoj s Formulom I ili njegova sol kako je definirano u bilo kojem od zahtjeva 1-7 primjenjuje prije jedne ili više pomoćnih terapijskih komponenti.
20. Kombinacija ili komplet za uporabu prema patentnom zahtjevu 19 naznačena time što jedna ili više pomoćnih terapijskih komponenti sadrži CTLA-4 mAb.
21. Kombinacija ili komplet za uporabu prema bilo kojem od patentnih zahtjeva 19-20 naznačena time što je hematološki poremećaj leukemija, more poželjno poželjnije odabran od akutne mijeloične leukemije (AML), akutne promijelocitne leukemije, akutne limfoblastične leukemije, i kronične mijelogene leukemije.
22. Kombinacija ili komplet za uporabu prema bilo kojem od patentnih zahtjeva 19-20 naznačena time što je rak odabran od karcinoma dojke, raka kože, raka kostiju, raka prostate, raka jetre, raka pluća, raka pluća ne-malih stanica, adenokarcinoma pluća skvamoznih ne-malih stanica, raka mozga, karcinoma grkljana, žučnog mjehura, gušterače, rektuma, paratireoidne žlijezde, štitnjače, nadbubrežne žlijezde, živčanog tkiva, glave i vrata, karcinoma debelog crijeva, želuca, bronha, i raka bubrega, karcinoma bazalnih stanica, karcinoma skvamoznih stanica i ulceroznog i papilarnog tipa, metastatskog karcinoma kože, osteo sarkoma, Ewingovog sarkoma, sarkoma stanica retikuluma, mijeloma, tumora velikih stanica, tumora pluća malih stanica, tumora stanica otočića, primarnog tumora mozga, akutnih i kroničnih limfocitnih i granulocitnih tumora, tumora vlasastih stanica, adenoma, hiperplazije, medularnog karcinoma, feokromocitoma, mukoznog neuroma, crijevnih ganglioneroma, hiperplastičnog tumora živca rožnice, tumora marfanoidnog habitusa, Wilmsovog tumora, seminoma, tumora jajnika, karcinoma jajnika otpornih na platinu, lejomioma maternice, cervikalne displazije i karcinoma in situ, neuroblastoma, retinoblastoma, sarkoma mekog tkiva, malignog karcinoida, mycosis fungoides, rabdomiosarkoma, Kaposijevog sarkoma, osteogenog sarkoma, maligne hiperkalcemije, tumora bubrežnih stanica, polcitiemije vera, adenokarcinoma, glioblastoma multiforme, leukemije, limfoma, melanoma, epidermoidnih karcinoma, hepatocelularnog karcinoma i solidnog tumora.
23. Kombinacija ili komplet za uporabu prema bilo kojem od patentnih zahtjeva 19-20 naznačena time što je bolest povezana s abnormalnom sintezom hemoglobina odabrana od anemije srpastih stanica i β-talasemije.
24. Kombinacija ili komplet za uporabu prema bilo kojem od patentnih zahtjeva 19-20 naznačena time što je MDS odabran od niskog, srednjeg i visokorizičnog MDS i mijeloproliferativnih neoplazmi.
25. Kombinacija prema bilo kojem od patentnih zahtjeva 1-11 ili komplet prema bilo kojem od patentnih zahtjeva 12-15 naznačena time što je namijenjena uporabi u terapiji ili profilaksi.
26. Kombinacija ili komplet za uporabu prema bilo kojem od patentnih zahtjeva 19-24 naznačena time što se sastoji od davanja spoja s Formulom (I) subjektu u skladu s režimom doziranja svakog dana tijekom 5 dana, odmah nakon toga slijede dva dana bez doziranja, nakon čega slijedi davanje jedne ili više pomoćnih terapijskih komponenti.
27. Kombinacija ili komplet za uporabu prema patentnom zahtjevu 26, naznačena time što se sastoji od davanja spoja s Formulom (I) subjektu u skladu s režimom doziranja svakog dana tijekom 5 dana, odmah nakon toga slijede dva dana bez doziranja, nakon čega slijedi davanje pomoćne (pomoćnih) terapijskih komponenti koje sadrže CTLA-4 mAb.
28. Kombinacija ili komplet prema bilo kojem od patentnih zahtjeva 1 do 18, naznačena time što jedna ili više pomoćnih terapijskih komponenti nadalje sadrži adjuvans.
29. Kombinacija ili komplet prema patentnom zahtjevu 28 naznačena time što je navedeni adjuvans ligand receptora za prepoznavanje patogena (PRR).
30. Kombinacija ili komplet prema patentnom zahtjevu 28 naznačena time što navedeni adjuvans sadrži TLR ligand, poželjno jedan ili više od TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10 i TLR11.
HRP20191171TT 2013-03-01 2019-06-27 Kombinacije lijekova HRP20191171T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361771525P 2013-03-01 2013-03-01
US201361887165P 2013-10-04 2013-10-04
EP14710728.8A EP2961388B1 (en) 2013-03-01 2014-02-27 Drug combinations
PCT/US2014/019137 WO2014134355A1 (en) 2013-03-01 2014-02-27 Drug combinations

Publications (1)

Publication Number Publication Date
HRP20191171T1 true HRP20191171T1 (hr) 2019-10-04

Family

ID=50288308

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191171TT HRP20191171T1 (hr) 2013-03-01 2019-06-27 Kombinacije lijekova

Country Status (25)

Country Link
US (2) US20160015805A1 (hr)
EP (2) EP3563836A1 (hr)
JP (2) JP6514647B2 (hr)
KR (1) KR20150125963A (hr)
CN (2) CN110448566A (hr)
AU (1) AU2014223348B2 (hr)
CA (1) CA2902433A1 (hr)
CY (1) CY1122554T1 (hr)
DK (1) DK2961388T3 (hr)
ES (1) ES2734023T3 (hr)
HK (1) HK1219663A1 (hr)
HR (1) HRP20191171T1 (hr)
HU (1) HUE044430T2 (hr)
IL (2) IL240894B (hr)
LT (1) LT2961388T (hr)
MX (2) MX366967B (hr)
PH (2) PH12015501905A1 (hr)
PL (1) PL2961388T3 (hr)
PT (1) PT2961388T (hr)
RU (2) RU2019138702A (hr)
SA (1) SA515360959B1 (hr)
SG (2) SG11201506727RA (hr)
SI (1) SI2961388T1 (hr)
WO (1) WO2014134355A1 (hr)
ZA (2) ZA201506150B (hr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
UA116528C2 (uk) 2011-08-30 2018-04-10 Астекс Фармасьютікалз, Інк. Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR20210149870A (ko) 2014-05-13 2021-12-09 메디뮨 리미티드 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
WO2016010879A1 (en) * 2014-07-15 2016-01-21 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
US10537626B2 (en) 2014-10-07 2020-01-21 Cytlimic Inc. HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
WO2016061231A1 (en) * 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TW202115102A (zh) 2015-03-09 2021-04-16 日商賽多利克公司 來自gpc3之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法
JP6311094B2 (ja) 2015-04-07 2018-04-18 サイトリミック株式会社 医薬
US10485764B2 (en) * 2015-07-02 2019-11-26 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
EP3527216B1 (en) 2016-10-11 2024-02-14 NEC Corporation A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
AU2018310857A1 (en) 2017-08-03 2020-02-13 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
WO2019126257A1 (en) * 2017-12-21 2019-06-27 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer
CN108948203B (zh) * 2018-08-09 2019-06-04 南京鼓楼医院 抗pd-1单克隆抗体及其制备方法和应用
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
JP7460094B2 (ja) * 2020-04-24 2024-04-02 ジェネクシン・インコーポレイテッド 子宮頸がんの治療方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
DK1659179T3 (da) 1998-02-05 2011-10-10 Glaxosmithkline Biolog Sa Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination
KR100856446B1 (ko) 1998-12-23 2008-09-04 화이자 인크. Ｃｔｌａ－４에 대한 인간 단일클론 항체
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US20030148973A1 (en) 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
WO2005033278A2 (en) 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
DE602005012686D1 (de) * 2004-05-26 2009-03-26 Biovaxim Ltd Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von cngen und behandlungsverfahren dafür
AU2005300315A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer
JP2008526760A (ja) 2004-12-29 2008-07-24 マンカインド コーポレイション 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN102596204B (zh) * 2009-07-06 2016-11-23 波涛生命科学有限公司 新的核酸前药及其使用方法
AU2009350151B2 (en) * 2009-07-20 2015-07-16 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
EP2486061A4 (en) * 2009-10-06 2013-08-28 Angiochem Inc COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTICS
GB201006096D0 (en) * 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
CA2810668A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
RU2016147206A (ru) * 2011-04-15 2018-10-19 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
UA116528C2 (uk) * 2011-08-30 2018-04-10 Астекс Фармасьютікалз, Інк. Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування
US11083743B2 (en) * 2013-02-21 2021-08-10 Michele Maio DNA hypomethylating agents for cancer therapy

Also Published As

Publication number Publication date
IL240894B (en) 2020-10-29
JP6514647B2 (ja) 2019-05-15
JP2019142911A (ja) 2019-08-29
MX2015011147A (es) 2016-04-28
CY1122554T1 (el) 2021-01-27
RU2015141628A3 (hr) 2018-03-07
CN105025884B (zh) 2019-08-20
ES2734023T3 (es) 2019-12-03
MX2019008822A (es) 2019-09-26
SG10201707135RA (en) 2017-10-30
US20160015805A1 (en) 2016-01-21
NZ750690A (en) 2020-09-25
US20200009247A1 (en) 2020-01-09
PH12019550222A1 (en) 2021-10-04
SI2961388T1 (sl) 2019-10-30
SA515360959B1 (ar) 2019-04-03
PT2961388T (pt) 2019-07-11
IL240894A0 (en) 2015-10-29
KR20150125963A (ko) 2015-11-10
EP2961388B1 (en) 2019-04-24
CN110448566A (zh) 2019-11-15
LT2961388T (lt) 2019-08-26
PL2961388T3 (pl) 2019-10-31
HK1219663A1 (zh) 2017-04-13
AU2014223348A1 (en) 2015-09-03
MX366967B (es) 2019-07-31
WO2014134355A1 (en) 2014-09-04
ZA201506150B (en) 2019-11-27
IL277385A (en) 2020-11-30
PH12015501905A1 (en) 2016-01-11
HUE044430T2 (hu) 2019-10-28
CA2902433A1 (en) 2014-09-04
RU2015141628A (ru) 2017-04-06
SG11201506727RA (en) 2015-09-29
JP2016510030A (ja) 2016-04-04
ZA201905426B (en) 2022-07-27
RU2708246C2 (ru) 2019-12-05
NZ711757A (en) 2020-09-25
EP2961388A1 (en) 2016-01-06
CN105025884A (zh) 2015-11-04
EP3563836A1 (en) 2019-11-06
RU2019138702A (ru) 2020-01-27
AU2014223348B2 (en) 2018-12-13
DK2961388T3 (da) 2019-07-08

Similar Documents

Publication Publication Date Title
HRP20191171T1 (hr) Kombinacije lijekova
JP2016510030A5 (hr)
ES2790414T3 (es) Terapia de combinación con un inhibidor de topoisomerasa
EP3730152A1 (en) Combination drug including tlr7 agonist
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
RU2014152107A (ru) Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака
CO6630134A2 (es) Formulación orales y sales lipofílicas de metilnaltrexona
ES2395401T3 (es) kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer
EP3102585A1 (en) Boronic acid esters and pharmaceutical formulations thereof
Georgieva et al. Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells
TWI332007B (en) Use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals
KR20060134059A (ko) 종양 억제 활성을 갖는 화합물
KR102600728B1 (ko) 암 치료를 위한 화합물, 조성물 및 이것의 용도
US20080069901A1 (en) Therapeutic Agent for Metastatic Cancer and Cancer Metastasis Inhibitor
BR112020010839A2 (pt) composição farmacêutica para intensificar o efeito antitumoral por inibidor de ponto de verificação imunológico e uso de composto na produção de um medicamento para intensificar o referido efeito antitumoral
Topçu Synthesis of novel bifuntional bisphosphonates
NZ711757B2 (en) Drug combinations comprising derivatives of decitabine
NZ750690B2 (en) Drug combinations comprising derivatives of decitabine